ARL6

Across TCGA pan-cancer cohorts, ARL6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARL6 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARL6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where ARL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.328	0.889	.014	27	view →
PDAC	OS	Median	II,III,IV	0.625	0.430	.006	27	view →
LSCC	OS	Median	All	0.806	0.953	<.001	8	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.852	.026	5	view →
LUAD	OS	Quartile	III,IV	0.711	1.000	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARL6–HNSC (DFS)

Open the HNSC breakdown →